 MADISON, Wis. and SEATTLE, March 17, 2021 GLOBE NEWSWIRE -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells iPSC technologies, and Sana Biotechnology, Inc. NASDAQ: SANA, a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics iPSC platform for the development of commercial cell therapies. As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells. 